Secretariat Lead of the G20’s Global AMR R&D Hub: Could this be you?

Dear All:

As you may know, the G20 are establishing an AMR R&D Hub that will encourage and promote coordinated global action on AMR. The hub will be based in the Berlin office of the German Center for Infection Research (DZIF) and Germany will finance it for the first three years. There is now a public call to recruit the leader of this hub. Here is the key text from the the online job description (emphasis is mine):

In their Declaration from July 7 and 8, 2017 the G20 Leaders “call for a new international R&D Collaboration Hub to maximize the impact of existing and new antimicrobial basic and clinical research initiatives as well as product development”. This Global AMR R&D Hub shall promote high-level coordination and alignment of the existing public and private funding and leverage further investments for AMR R&D initiatives on a national and/or international level. The Global AMR R&D Hub shall become a central platform to provide guidance for governments and non-governmental funders on R&D funding priorities in the field. The scope of the Global AMR R&D Hub is embedded in a comprehensive One Health Approach, comprising human and animal health as well as environmental aspects. Initially, the activities of the Global AMR R&D Hub shall focus on enabling the development of urgently needed products for the prevention, treatment and diagnosis of bacterial infections in humans.

For the implementation of the Global AMR R&D Hub a secretariat with up to five employees (including the position announced below) will be established within the German Center for Infection Research (DZIF) in Berlin, Germany. We are currently searching for one Secretariat Lead (Senior Level).

Could this be you or somebody you know? Please be sure to share this interesting and important job opportunity! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

CDC-FDA webinar: Developing drugs to prevent healthcare-associated infections (30 Aug 2022)

Dear All, A quick note today to call your attention to an upcoming webinar that will be of wide interest. Substantial new details have been added to the online agenda materials for the 30 August 2022 (virtual, 8.30a-5.00p ET) webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very

US Senate and House / Call for Pull incentives in FY23 budget

Dear All, The US Government is now building its budget for FY23 (Federal Year 2023, really runs 1 Oct 22 to 30 Sep 23). We had proposals from the House for the Department of Health and Human Services (DHHS) budget in late June;  and the proposal from Senate was released on 28 Jul 2022. Each

WHO Vaccine pipeline review; CDC on impact of COVID on AMR

Dear All, WHO continues to crank out those pipeline reviews … now we have one for bacterial vaccines! Go here for the press release and here for the report. The report considers data from 2010 forward and (interestingly) provides data on both active and failed projects. The review identified 94 active preclinical candidates and 61

IDWeek 2022: New pipeline sessions seek presentation of therapeutics and diagnostics!

Dear All: I have learned that the program for IDWeek 2022 will have specific dedicated pipeline sessions for therapeutics and diagnostics. The online details are relatively scant, but my understanding is that the therapeutics of interest for these sessions include antibacterials, antifungals, and non-HIV, non-COVID antiviral agents. There do not appear to be any constraints

Scroll to Top